This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-18 November 2022
Live In-Person Conference Delivered 15-18 NovemberAustria Center Vienna

Michela Brambatti, M.D.
Director, Clinical Development at Ionis Pharmaceuticals


Michela Brambatti is a board-certified cardiologist and currently Associate Director in the Clinical Development department at Ionis Pharmaceuticals in Carlsbad, California. At Ionis, she focuses on early and late phase drug development for cardiac amyloidosis, HFrEF, and HFpEF. Before joining Ionis, she worked in the Department of Medicine at the University of California San Diego where she made significant contributions in natural history studies and the early development of gene therapy for Danon Disease. She published over 40 peer-reviewed manuscripts in the field of heart failure and rare cardiomyopathies. She completed medical school and cardiology fellowship at the Marche Polytechnic University (Italy), a research fellowship in cardiovascular epidemiology at McMaster University (Canada), and an MS degree at the University of California, San Diego.

Agenda Sessions

  • Antisense Oligonucleotides Targeting the Angiotensinogen: A Novel Therapeutic Approach in the Cardiovascular Space